Adagene announces progress in program for ADG126 and KEYTRUDA

Adagene (ADAG) announced progress and expansion of the clinical collaboration development program for its masked, anti-CTLA-4 SAFEbody, ADG126 in combination with Merck & Co. (MERK), Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, or pembrolizumab, in patients with metastatic microsatellite-stable, or MSS, colorectal cancer, or CRC. “Following completion of enrollment of 12 additional patients at the end of last year, together with our ongoing expansion plans, we are on track to deliver data in 2024 that support the findings released at the recent ASCO-GI Symposium demonstrating the safety and efficacy profile of ADG126 in combination with pembrolizumab in MSS CRC,” said Peter Luo, Chairman, CEO and President of R&D at Adagene. He continued, “To address the requirements for Project Optimus by FDA, we have initiated evaluation of ADG126 20 mg/kg loading doses in combination with pembrolizumab, which we believe can unlock even greater efficacy for MSS CRC in planned cohort expansion, while still maintaining a robust safety profile. Additionally, we are now cleared to evaluate ADG126 in combination with pembrolizumab in China, strengthening our efficacy evaluation with additional patients enrolled at unprecedented dosing regimens for anti-CTLA-4 therapy.”